Cumulative Revenue Reaches KRW 1.2376 Trillion in the First Three Quarters
Prescription Growth Continues for Key Drugs Including Rosuzet
Beijing Hanmi Recovers; Hanmi Fine Chemical Returns to Profitability

Hanmi Pharmaceutical surpassed KRW 1.2 trillion in cumulative revenue for the first three quarters of this year, boosted by expanded prescriptions of its flagship prescription medicines. Key products such as Rosuzet led growth, while results also improved at its Chinese subsidiary and its affiliate specializing in active pharmaceutical ingredients. However, third-quarter operating profit fell by about 30% year on year.


Hanmi Pharmaceutical disclosed on October 27 that it recorded consolidated revenue of KRW 377.4 billion, operating profit of KRW 37.8 billion and net profit of KRW 14 billion in the third quarter of this year. Revenue rose 4.2% year on year, while operating profit and net profit fell 31.3% and 69.1%, respectively.


The Hanmi Group headquarters in Songpa-gu, Seoul. Hanmi Pharmaceutical.

The Hanmi Group headquarters in Songpa-gu, Seoul. Hanmi Pharmaceutical.

View original image

Hanmi Pharmaceutical said, "Operating profit and net profit declined from the previous quarter due to a base effect from the one-time recognition of an upfront payment under the sonofepegutide technology transfer agreement. However, the company is maintaining stable growth, supported by solid growth in key products such as Rosuzet, a gradual recovery at Beijing Hanmi Pharmaceutical following its strategy to respond to China's centralized procurement system, and improved profitability at Hanmi Fine Chemical."


Hanmi Pharmaceutical's cumulative third-quarter outpatient prescription sales, based on UBIST data, reached KRW 783.5 billion. Third-quarter outpatient prescription sales of Rosuzet, a combination drug for dyslipidemia, rose 10.6% year on year to KRW 65.2 billion. The company's other sales included KRW 38.2 billion from its Amosartan Family hypertension product line and KRW 15.2 billion from its Esomezol Family gastroesophageal reflux disease product line.


Beijing Hanmi Pharmaceutical, the company's Chinese subsidiary, recorded revenue of KRW 79.3 billion in the third quarter of this year. It showed a gradual recovery as it pursued sales strategies including strategic bidding and expanded supply volumes to respond to China's centralized procurement system. The company said it has suspended new transactions with distributors of concern until Beijing Hanmi collects its receivables, and is further strengthening its internal control system.


Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients (APIs), recorded third-quarter revenue of KRW 22.8 billion, up 32.6% year on year. Despite intensifying competition in the market for Cepha-class antibiotics, operating profit and net profit returned to the black, supported by an increase in new orders for high-margin contract development and manufacturing (CDMO) services.


In research and development (R&D), Hanmi is advancing around 30 innovative drug pipeline candidates in areas including obesity and metabolic disorders, rare diseases and cancer. It is strengthening its global technological competitiveness through a differentiation strategy that incorporates new modalities (therapeutic approaches). With the launch of Epe, a GLP-1 obesity drug developed using Hanmi's proprietary technology and the first of its kind developed in Korea, approaching, the company is building a full-cycle portfolio of personalized obesity treatments through its H.O.P. Project, which will introduce next-generation obesity drugs in stages.



A Hanmi Pharmaceutical official said, "As a leading R&D-focused pharmaceutical company in Korea, we are continuing to innovate to strengthen our core competitiveness and secure future growth engines. We will continue to focus our capabilities on new drug research and development and work to enhance shareholder value to achieve sustainable growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing